



DAICEL CORPORATION

January 8, 2021

DAICEL Corporation

Announcement of Investigator-Initiated Clinical Trial on COVID-19 DNA Vaccination Using Daicel's Novel Drug Delivery Device

Daicel Corporation (Headquarters: Kita-ku, Osaka, President & CEO: Yoshimi Ogawa, hereinafter: "Daicel") announced that an investigator initiated clinical trial for the purpose of vaccination of registered subjects (healthy adults) using Daicel's novel drug delivery device has been started with a "Phase I / II study of intradermal inoculation of COVID-19 DNA vaccine (AG0302-COVID19)", conducted by Osaka University Hospital (Location: Suita-shi, Osaka, Director: Yuichiro Doki).

Daicel is participating in the Joint DNA vaccine development against COVID-19 conducted by Osaka University (Head office: Suita-shi, Osaka, President: Shojiro Nishio) and AnGes Inc. (Head Office: Ibaraki-shi, Osaka, President and CEO: Ei Yamada).

In this investigator-initiated clinical trial, Daicel's novel drug delivery device (DC-MD3A) will be applied for intradermal administration of the investigational drug to evaluate the efficacy and safety of intradermal administration of a DNA vaccine.

Summary of the clinical trial

DNA vaccines for the SARS-CoV-2 virus are being developed, but they require intramuscular injections for the delivery. In the Osaka University research, the pyro-drive jet injector uses intradermal gas propulsion, which is expected to lower the amount of vaccine needed to one-fifth or even one-tenth that needed for intramuscular injections. In the current trial, both the efficacy and safety of the intradermal delivery will be evaluated.

Click here for details of this clinical trial : <http://www.med.osaka-u.ac.jp/eng/archives/6347>

<Contact for inquiry on this subject>

IR & Corporate Communications

Daicel Corporation

TEL: +81-3-6711-8121